October 2007
Worldwide Biotech;Oct2007, Vol. 19 Issue 10, p4
Trade Publication
The article reports on the acquisition by Clinical Data Inc. of Epidauros Biotechnologie AG in a cash transaction valued at 8.75 million euros. It is noted that an intellectual property portfolio which includes biomarkers in genes relating to drug transporters and cytochrome P450 drug metabolizing genes are among the assets acquired by the company. President and CEO Drew Fromkin said they are pleased to complete the deal because they believe it will enhance the company's ability to bring valuable, proprietary pharmacogenetic tests to market.


Related Articles

  • Clinical Data acquires Epidauros, German genetic biomarker firm.  // Medical Device Daily;8/24/2007, Vol. 11 Issue 162, p1 

    The article reports on the acquisition of Epidauros Biotechnologie by the U.S. firm Clinical Data. According to Clinical Data, Epidauros brings an established portfolio of genetic biomarkers, expertise in genetic biomarker discovery and a pharmacogenomics services business. Clinical Data CEO...

  • Clinical Data acquires Epidauros.  // Diagnostics & Imaging Week;8/30/2007, Vol. 10 Issue 35, p9 

    The article reports on the purchase of Epidauros Biotechnologie of Bernried, Germany by Clinical Data of Newton, Massachusetts. Under the deal, Clinical Data acquired the intellectual property portfolio of Epidauros which includes biomarkers in genes relating to prominent drug transporters....

  • Clinical Data acquires Epidauros.  // European Pharmaceutical Executive;Oct2007, p14 

    The article reports that Clinical Data Inc. has acquired privately held Epidauros Biotechnologie AG in a cash transaction valued at €8.75 million. Epidauros brings to Clinical Data an established portfolio of proprietary genetic biomarkers, expertise in genetic biomarker discovery...

  • Clinical Data acquires genetic biomarker firm Epidauros.  // Biomedical Business & Technology;Sep2007, Vol. 30 Issue 9, p21 

    The article reports the acquisition of Epidauros Biotechnologie by Clinical Data in August 2007. Post acquisition, Epidauros CEO Michael Lutz will join the PGxHealth division of Clinical Data. The financial terms of the deal are disclosed. Comments from Drew Fromkin, president and CEO of...

  • OTHER NEWS TO NOTE.  // BioWorld Today;8/24/2007, Vol. 18 Issue 165, p2 

    This section offers news briefs on the biotechnology industry. Apogee Technology Inc. made an agreement with the Vaccine and Infectious Disease Organization to support Apogee's advancement of intradermal technology delivery of vaccines and drugs. Epidauros Biotechnologie AG was acquired by...

  • PHARMACOGENETICS MAY INFLUENCE TACROLIMUS DAILY DOSE, BUT NOT URINARY TUBULAR DAMAGE MARKERS IN THE LONG-TERM PERIOD AFTER RENAL TRANSPLANTATION. Stefanović, Nikola Z.; Cvetković, Tatjana P.; Veličković-Radovanović, Radmila M.; Jevtović-Stoimenov, Tatjana M.; Vlahović, Predrag M.; Stojanović, Ivana R.; Pavlović, Dusica D. // Journal of Medical Biochemistry;Oct2015, Vol. 34 Issue 4, p422 

    Background: The primary goal of this study was to evaluate the influence of cytochrome P450 (CYP) 3A5 (6986A>G) and ABCB1 (3435C>T) polymorphisms on tacrolimus (TAC) dosage regimen and exposure. Second, we evaluated the influence of TAC dosage regimen and the tested polymorphisms on renal...

  • CYP2D6 Genotype and Adjuvant Tamoxifen. Berry, D A // Clinical Pharmacology & Therapeutics;Aug2014, Vol. 96 Issue 2, p138 

    A study by Province et al. for the International Tamoxifen Pharmacogenomics Consortium (ITPC) appeared in a recent issue of this journal.1 In addition to discussing this study and biomarker studies in general, I provide an overall assessment of the evidence regarding testing for CYP2D6 in making...

  • CYP2D6 Genotype and Tamoxifen: Considerations for Proper Nonprospective Studies. Goetz, M P; Ingle, J N // Clinical Pharmacology & Therapeutics;Aug2014, Vol. 96 Issue 2, p141 

    The article comments on data from the International Tamoxifen Pharmacogenomics Consortium (ITPC) about the link between tamoxifen treatment outcomes and CYP2D6 genotype. Topics discussed include the use of CYP2D6 genotype as a biomarker associated with tamoxifen effectiveness, CYP2D6 status in...

  • Use of Biochemical Markers for the Assessment of Organic Pollutant Contamination of the Vltava river, Czech Republic. Marcela Havelková; Slatinská, Iveta; Široká, Zuzana; Blahová, Jana; Krijt, Jan; Randák, Tomáš; Žlábek, Vladimír; Haruštiaková, Danka; Jarkovský, Jiří; Svobodová, Zdeńka // Acta Veterinaria Brno;Sep2009, Vol. 78 Issue 3, p513 

    In this study, selected biochemical markers - cytochrome P450 (CYP 450), ethoxyresorufin-O-deethylase (EROD), glutathione S-transferase (GST) and glutathione (GSH) - were measured in chub (Leuciscus cephalus L.) liver samples obtained from three locations on the Vltava river (Podolí, Podbaba...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics